Literature DB >> 19815124

Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging.

Luuk J Rijzewijk1, Rutger W van der Meer, Hildo J Lamb, Hugo W A M de Jong, Mark Lubberink, Johannes A Romijn, Jeroen J Bax, Albert de Roos, Jos W Twisk, Robert J Heine, Adriaan A Lammertsma, Johannes W A Smit, Michaela Diamant.   

Abstract

OBJECTIVES: This study was designed to evaluate myocardial substrate and high-energy phosphate (HEP) metabolism in asymptomatic men with well-controlled, uncomplicated type 2 diabetes with verified absence of cardiac ischemia, and age-matched control subjects, and to assess the association with myocardial function.
BACKGROUND: Metabolic abnormalities, particularly an excessive exposure of the heart to circulating nonesterified fatty acids and myocardial insulin resistance are considered important contributors to diabetic cardiomyopathy in animal models of diabetes. The existence of myocardial metabolic derangements in uncomplicated human type 2 diabetes and their possible contribution to myocardial dysfunction still remain undetermined.
METHODS: In 78 insulin-naive type 2 diabetes men (age 56.5 +/- 5.6 years, body mass index 28.7 +/- 3.5 kg/m(2), glycosylated hemoglobin A(1c) 7.1 +/- 1.0%; expressed as mean +/- SD) without cardiac ischemia and 24 normoglycemic control subjects (age 54.5 +/- 7.1 years, body mass index 27.0 +/- 2.5 kg/m(2), glycosylated hemoglobin A(1c) 5.3 +/- 0.2%), we assessed myocardial left ventricular (LV) function by magnetic resonance imaging, and myocardial perfusion and substrate metabolism by positron emission tomography using H(2)(15)O, carbon (11)C-palmitate, and 18-fluorodeoxyglucose 2-fluoro-2-deoxy-D-glucose. Cardiac HEP metabolism was assessed by phosphorous P 31 magnetic resonance spectroscopy.
RESULTS: In patients, compared with control subjects, LV diastolic function (E/A ratio: 1.04 +/- 0.25 vs. 1.26 +/- 0.36, p = 0.003) and myocardial glucose uptake (260 +/- 128 nmol/ml/min vs. 348 +/- 154 nmol/ml/min, p = 0.015) were decreased, whereas myocardial nonesterified fatty acid uptake (88 +/- 31 nmol/ml/min vs. 68 +/- 18 nmol/ml/min, p = 0.021) and oxidation (85 +/- 30 nmol/ml/min vs. 63 +/- 19 nmol/ml/min, p = 0.007) were increased. There were no differences in myocardial HEP metabolism or perfusion. No association was found between LV diastolic function and cardiac substrate or HEP metabolism.
CONCLUSIONS: Patients versus control subjects showed impaired LV diastolic function and altered myocardial substrate metabolism, but unchanged HEP metabolism. We found no direct relation between cardiac diastolic function and parameters of myocardial metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815124     DOI: 10.1016/j.jacc.2009.04.074

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  105 in total

1.  Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance.

Authors:  Janet B McGill; Linda R Peterson; Pilar Herrero; Ibrahim M Saeed; Carol Recklein; Andrew R Coggan; Amanda J Demoss; Kenneth B Schechtman; Carmen S Dence; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2011-04-23       Impact factor: 5.952

2.  Upregulation of eNOS and unchanged energy metabolism in increased susceptibility of the aging type 2 diabetic GK rat heart to ischemic injury.

Authors:  Martine Desrois; Kieran Clarke; Carole Lan; Christiane Dalmasso; Mark Cole; Bernard Portha; Patrick J Cozzone; Monique Bernard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

3.  Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans.

Authors:  Linda R Peterson; Ibrahim M Saeed; Janet B McGill; Pilar Herrero; Kenneth B Schechtman; Ratnasiri Gunawardena; Carol L Recklein; Andrew R Coggan; Amanda J DeMoss; Carmen S Dence; Robert J Gropler
Journal:  Obesity (Silver Spring)       Date:  2011-08-04       Impact factor: 5.002

Review 4.  Recent advances in metabolic imaging.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

5.  Sustained cardiac remodeling after a short-term very low calorie diet in type 2 diabetes mellitus patients.

Authors:  Jacqueline T Jonker; Marieke Snel; Sebastiaan Hammer; Ingrid M Jazet; Rutger W van der Meer; Hanno Pijl; A Edo Meinders; Albert de Roos; Johannes W A Smit; Johannes A Romijn; Hildo J Lamb
Journal:  Int J Cardiovasc Imaging       Date:  2013-10-16       Impact factor: 2.357

Review 6.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Is diabetic cardiomyopathy a specific entity?

Authors:  Mitja Letonja; Danijel Petrovič
Journal:  World J Cardiol       Date:  2014-01-26

Review 8.  Role of cardiac MRI in diabetes.

Authors:  Ravi V Shah; Siddique A Abbasi; Raymond Y Kwong
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

9.  Oral ethinylestradiol-levonorgestrel attenuates cardiac glycogen and triglyceride accumulation in high fructose female rats by suppressing pyruvate dehydrogenase kinase-4.

Authors:  Kehinde Samuel Olaniyi; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-01       Impact factor: 3.000

Review 10.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.